Abstract: PO2121
Hypophosphatemia in the Context of Hematopoietic Stem Cell Transplantation: An Underappreciated Complication
Session Information
- Transplantation: Clinical - Underrecognized Risk Factors, Traditional Considerations, and Outcomes
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 1902 Transplantation: Clinical
Authors
- Muthukumar, Thangamani, Weill Cornell Medicine, New York, New York, United States
- Flombaum, Carlos, Memorial Sloan Kettering Cancer Center, New York, New York, United States
Background
Hypophosphatemia (and hypokalemia) occur frequently in the context of hematopoietic allogeneic stem cell transplantation (allo-SCT) and during autologous SCT (auto-SCT) and have been attributed to uptake of these electrolytes by the reconstituting bone marrow. Similar metabolic complications can also occur after chemotherapy and during stem cell mobilization prior to auto SCT. These metabolic abnormalities have not been well described in the nephrology literature and in current textbooks of onconephrology.
Aim of the research was to describe the clinical course of patients with these electrolyte abnormalities in the context of SCT, chemotherapy and after bone marrow stimulation prior to SCT harvesting.
Methods
Chart review of patients undergoing SCT, after chemotherapy and SCT for harvesting.
Results
We identified 42 patients with 67 episodes of hypophosphatemia and hypokalemia. The clinical features and course are provided in the table.
Conclusion
Besides uptake of phosphorous and potassium by the reconstituting bone marrow under the stimulation of granulocyte colony a stimulation factor, other factors contributing to these metabolic abnormalities include poor oral intake, the use of phosphate binders, diuretics and losses during renal replacement therapy.